Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. 2003

Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
Division of Pharmaceutical Chemistry, University of Helsinki, Finland.

A multidimensional study on the glucuronidation of anabolic androgenic steroids and their phase I metabolites by 11 recombinant human UDP-glucuronosyltransferases (UGTs) was carried out using liquid chromatographic-tandem mass spectrometric analyses. Large differences between the enzymes with respect to the conjugation profiles of the 11 tested aglycones were detected. Two UGTs, 1A6 and 1A7, did not exhibit measurable activity toward any of the aglycones that were examined in this study. Regioselectivity was demonstrated by UGTs 1A8, 1A9, and 2B15 that preferentially catalyzed hydroxyl glucuronidation at the 17beta-position. Most of the other enzymes glucuronidated hydroxyl groups at both the 3alpha- and the 17beta-positions. Clear stereoselectivity was observed in glucuronidation of diastereomeric nandrolone metabolites (5alpha-estran-3alpha-ol-17-one and 5beta-estran-3alpha-ol-17-one), whereas such specificity was not seen when analogous methyltestosterone metabolites were assayed. UGTs 1A1, 1A3, 1A4, 1A8, 1A9, 1A10, 2B4, 2B7, and 2B15 readily glucuronidated 5alpha-androstane-3alpha,17beta-diol, but none of them exhibited methyltestosterone glucuronidation activity. In agreement with the latter observations, we found that the methyltestosterone glucuronidation activity of human liver microsomes is extremely low, whereas in induced rat liver microsomes it was significantly higher. The homology among UGTs 1A7 to 1A10 at the level of amino acid sequence is very high, and it was thus surprising to find large differences in their activity toward this set of aglycones. Furthermore, the high activity of UGT1A8 and 1A10 toward some of the substrates indicates that extrahepatic enzymes might play a role in the metabolism of anabolic androgenic steroids.

UI MeSH Term Description Entries
D008297 Male Males
D008696 Methandrostenolone A synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. It has little progestational activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188) Dehydromethyltestosterone,Metandienone,Methandienone,Dianabol,Metanabol,Nerobol
D008710 Methenolone A synthetic steroid that has been used for its anabolic action. Metenolone
D008777 Methyltestosterone A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL). 17 beta Methyltestosterone,17 beta-Hydroxy-17-methyl-4-androsten-3-one,17 beta-Methyltestosterone,17-Epimethyltestosterone,17-alpha-Methyltestosterone,17alpha-Methyl-Testosterone,17alpha-Methyltestosterone,17beta-Hydroxy-17-methyl-4-androsten-3-one,17beta-Methyltestosterone,Android (Methyltestoterone),Android-10,Android-25,Android-5,Mesteron,Mesterone,Metandren,Methitest,Oreton,Testoviron,Testred,Virilon,17 Epimethyltestosterone,17 alpha Methyltestosterone,17 beta Hydroxy 17 methyl 4 androsten 3 one,17alpha Methyl Testosterone,17alpha Methyltestosterone,17beta Hydroxy 17 methyl 4 androsten 3 one,17beta Methyltestosterone,Android 10,Android 25,Android 5
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D009277 Nandrolone C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. 19-Nortestosterone,Estrenolone,Norandrostenolone,Nortestosterone,17-Hydroxy-Estr-4-Ene-3-One,17beta-Hydroxy-19-Nor-4-Androsten-3-One,17beta Hydroxy 19 Nor 4 Androsten 3 One
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen

Related Publications

Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
August 2007, Molecular nutrition & food research,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
May 1993, Biochemical pharmacology,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
April 1998, Biochemical pharmacology,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
June 2007, Biochemical pharmacology,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
May 2005, Drug metabolism and disposition: the biological fate of chemicals,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
November 2000, Drug metabolism and disposition: the biological fate of chemicals,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
January 2008, The Journal of pharmacology and experimental therapeutics,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
September 2014, Chemico-biological interactions,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
September 2009, British journal of clinical pharmacology,
Tiia Kuuranne, and Mika Kurkela, and Mario Thevis, and Wilhelm Schänzer, and Moshe Finel, and Risto Kostiainen
November 2007, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!